ArticleClinical and translational gastroenterology2026
Alterations in the Gut Microbiota of Cirrhotic Patients With Sarcopenia and PH After TIPS.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role ofInternational journal of molecular sciences · 2026Review
- Navigating TIPS in the era of ageing and metabolic comorbidity: a contemporary narrative review of risk, resilience, and outcomes.Gastroenterology report · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTransjugular intrahepatic portosystemic shunt (TIPS) can effectively reduce portal hypertension (PH) and may be associated with improvement in muscle status; however, its impact on the gut microbiota and muscle condition remains unclear. Therefore, this prospective study aimed to evaluate gut microbiota alterations in patients with sarcopenia and PH after TIPS treatment.
methodsGut microbiota analysis was prospectively conducted in 20 cirrhotic patients with sarcopenia and PH receiving TIPS and their first-degree healthy family between December 2019 and July 2021 in our center. Fecal samples were collected before and 3 months after TIPS and analyzed by 16S rRNA sequencing. Microbial diversity and composition were assessed using standard bioinformatic pipelines. Sarcopenia was defined by L3 skeletal muscle index according to European Association for the Study of the Liver criteria.
resultsCompared with healthy controls, cirrhotic patients with sarcopenia and PH exhibited significantly reduced α-diversity (Chao1, Shannon, Simpson; all P < 0.001) and distinct β-diversity clustering, confirming gut dysbiosis. Although TIPS did not significantly alter overall α-diversity, a significant increase in the order Burkholderiales and a reduction in Pseudomonadales and Staphylococcales were detected after TIPS. Analysis of the family taxonomic rank revealed that TIPS was followed by an increase in a greater abundance of Ruminococcaceae and Sutterellaceae and decreased levels of Tannerellaceae, Marinifilaceae, and Pseudomonadaceae. At the genus level, after TIPS placement, increased levels of Lachnospiraceae _ND3007_group, Intestinibacter , Fusicatenibacter , and Faecalibacterium and lower abundances of Pseudomonas , Prevotella , Peptostreptococcus , Parabacteroides , Muribaculaceae , and Butyricimonas were detected. Sarcopenia reversal was observed in 25% of patients, characterized by enrichment of short-chain fatty acid-producing genera such as Faecalibacterium and Streptococcus , whereas patients without improvement showed high abundance of Fusicatenibacter and low levels of beneficial taxa. DISCUSSION: TIPS induces significant taxonomic shifts without changing overall diversity in cirrhotic patients with sarcopenia and PH, suggesting partial microbial restoration. Enrichment of short-chain fatty acid-producing bacteria may correlates with improved sarcopenia, whereas proinflammatory taxa may indicate poor recovery and higher risk of complications. These findings highlight the gut-muscle-liver axis and support microbiome-based biomarkers and interventions to optimize outcomes after TIPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.